Lexaria Bioscience (LEXX) Competitors $1.35 +0.11 (+8.87%) Closing price 09/22/2025 04:00 PM EasternExtended Trading$1.33 -0.02 (-1.48%) As of 09/22/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LEXX vs. ELUT, SLGL, PMVP, UNCY, ASRT, IGMS, IRD, IMUX, BYSI, and IZTCShould you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Elutia (ELUT), Sol-Gel Technologies (SLGL), PMV Pharmaceuticals (PMVP), Unicycive Therapeutics (UNCY), Assertio (ASRT), IGM Biosciences (IGMS), Opus Genetics (IRD), Immunic (IMUX), BeyondSpring (BYSI), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry. Lexaria Bioscience vs. Its Competitors Elutia Sol-Gel Technologies PMV Pharmaceuticals Unicycive Therapeutics Assertio IGM Biosciences Opus Genetics Immunic BeyondSpring Invizyne Technologies Elutia (NASDAQ:ELUT) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Does the media refer more to ELUT or LEXX? In the previous week, Elutia had 3 more articles in the media than Lexaria Bioscience. MarketBeat recorded 3 mentions for Elutia and 0 mentions for Lexaria Bioscience. Elutia's average media sentiment score of 0.67 beat Lexaria Bioscience's score of 0.00 indicating that Elutia is being referred to more favorably in the media. Company Overall Sentiment Elutia Positive Lexaria Bioscience Neutral Is ELUT or LEXX more profitable? Elutia has a net margin of -90.01% compared to Lexaria Bioscience's net margin of -1,849.19%. Elutia's return on equity of 0.00% beat Lexaria Bioscience's return on equity.Company Net Margins Return on Equity Return on Assets Elutia-90.01% N/A -54.08% Lexaria Bioscience -1,849.19%-157.22%-133.69% Do analysts prefer ELUT or LEXX? Elutia presently has a consensus target price of $7.00, indicating a potential upside of 530.63%. Lexaria Bioscience has a consensus target price of $4.00, indicating a potential upside of 196.30%. Given Elutia's higher probable upside, equities research analysts plainly believe Elutia is more favorable than Lexaria Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Lexaria Bioscience 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals & insiders believe in ELUT or LEXX? 74.0% of Elutia shares are owned by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 26.4% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk & volatility, ELUT or LEXX? Elutia has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Which has better earnings & valuation, ELUT or LEXX? Lexaria Bioscience has lower revenue, but higher earnings than Elutia. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M1.93-$53.95M-$1.06-1.05Lexaria Bioscience$460K57.40-$5.80M-$0.67-2.01 SummaryElutia beats Lexaria Bioscience on 12 of the 15 factors compared between the two stocks. Get Lexaria Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LEXX vs. The Competition Export to ExcelMetricLexaria BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.25M$3.16B$5.79B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-2.0121.03348.4626.86Price / Sales57.40447.99552.75125.65Price / CashN/A44.8326.0131.15Price / Book2.819.8316.256.50Net Income-$5.80M-$52.82M$3.29B$271.25M7 Day Performance-7.53%3.07%200.40%3.22%1 Month Performance70.28%5.37%184.37%8.11%1 Year Performance-57.28%16.89%334.77%26.42% Lexaria Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LEXXLexaria Bioscience3.2859 of 5 stars$1.35+8.9%$4.00+196.3%-58.6%$24.25M$460K-2.017Positive NewsGap DownELUTElutia3.1342 of 5 stars$1.88flat$8.00+325.5%-72.3%$79.70M$24.38M-1.77180SLGLSol-Gel Technologies0.5724 of 5 stars$27.55-1.5%N/A+289.0%$77.89M$11.54M-22.4050Positive NewsPMVPPMV Pharmaceuticals3.1853 of 5 stars$1.40-4.1%$5.50+292.9%-10.7%$77.37MN/A-0.8950News CoveragePositive NewsAnalyst RevisionUNCYUnicycive Therapeutics2.331 of 5 stars$4.37+0.2%$60.00+1,273.0%-13.9%$77M$680K-1.069ASRTAssertio1.8325 of 5 stars$0.80+0.9%$2.38+195.1%-28.7%$76.78M$124.96M-1.7920IGMSIGM Biosciences2.7371 of 5 stars$1.27flat$4.89+285.0%N/A$76.57M$145.05M-1.41190IRDOpus Genetics2.4214 of 5 stars$1.40+10.2%$7.33+423.8%N/A$76.08M$10.99M-0.7314Positive NewsGap UpHigh Trading VolumeIMUXImmunic2.0502 of 5 stars$0.83+9.1%$8.33+904.0%-50.3%$75.07MN/A-0.8870Positive NewsGap UpBYSIBeyondSpringN/A$1.90+2.2%N/A-16.0%$75.02M$1.75M0.0080IZTCInvizyne TechnologiesN/A$11.96+13.1%N/AN/A$74.77MN/A0.0029 Related Companies and Tools Related Companies ELUT Competitors SLGL Competitors PMVP Competitors UNCY Competitors ASRT Competitors IGMS Competitors IRD Competitors IMUX Competitors BYSI Competitors IZTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LEXX) was last updated on 9/23/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexaria Bioscience Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexaria Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LEXX Stock Alerts